Systemic diseases often have common characteristics. The aim of this study was to investigate the feasibility of targeting common pathological metabolism to inhibit the progression of malignant and proliferative diseases.
Results:
Gefitinib-resistant (G-R) nonsmall-cell lung cancer (NSCLC) and rheumatoid arthritis (RA) were studied as conditions representative of malignant and proliferative diseases, respectively. Strong lipogenic activity and high expression of sterol regulatory element-binding protein 1 (SREBP1) were found in both G-R NSCLC cells and synovial fibroblasts from RA patients (RASFs). Berberine (BBR), an effective suppressor of SREBP1 and lipogenesis regulated through reactive oxygen species (ROS)/AMPK pathway, selectively inhibited the growth of G-R NSCLC cells and RASFs but not that of normal cells. It effectively caused mitochondrial dysfunction, activated ROS/AMPK pathway, and finally suppressed cellular lipogenesis and cell proliferation. Addition of ROS blocker, AMPK inhibitor, and palmitic acid significantly reduced the effect of BBR. In an in vivo study, treatment of BBR led to significant inhibition of mouse tumor xenograft growth and remarkably slowed down the development of adjuvant-induced arthritis in rats.
Innovation and Conclusion:
Targeting ROS/AMPK/lipogenesis signaling pathway selectively inhibited the growth of G-R NSCLC cells and the progress of RASFs in vitro and in vivo, which provides a new avenue for treating malignancies and proliferative diseases.
Get full access to this article
View all access options for this article.
References
1.
ArmakaM, ApostolakiM, JacquesP, KontoyiannisDL, ElewautD, and KolliasG. Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases. J Exp Med, 205: 331–337, 2008.
2.
BriotA, CivelekM, SekiA, HoiK, MackJJ, LeeSD, KimJ, HongC, YuJ, FishbeinGA, VakiliL, FogelmanAM, FishbeinMC, LusisAJ, TontonozP, NavabM, BerlinerJA, and Iruela-ArispeML. Endothelial NOTCH1 is suppressed by circulating lipids and antagonizes inflammation during atherosclerosis. J Exp Med, 212: 2147–2163, 2015.
3.
ChoyE, GaneshalingamK, SembAG, SzekaneczZ, and NurmohamedM. Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology, 53: 2143–2154, 2014.
4.
CurrieE, SchulzeA, ZechnerR, WaltherTC, and FareseRVJr. Cellular fatty acid metabolism and cancer. Cell Metab, 18: 153–161, 2013.
5.
DeBerardinisRJ and ThompsonCB. Cellular metabolism and disease: what do metabolic outliers teach us?. Cell, 148: 1132–1144, 2012.
6.
DengJ, LiuY, YangM, WangS, ZhangM, WangX, KoKH, HuaZ, SunL, CaoX, and LuL. Leptin exacerbates collagen-induced arthritis via enhancement of Th17 cell response. Arthritis Rheum, 64: 3564–3573, 2012.
7.
DowlingRJ, NiraulaS, StambolicV, and GoodwinPJ. Metformin in cancer: translational challenges. J Mol Endocrinol, 48: R31–R43, 2012.
8.
EscribaPV, Gonzalez-RosJM, GoniFM, KinnunenPK, VighL, Sanchez-MagranerL, FernandezAM, BusquetsX, HorvathI, and Barcelo-CoblijnG. Membranes: a meeting point for lipids, proteins and therapies. J Cell Mol Med, 12: 829–875, 2008.
9.
FinkelsteinJ, HeemelsMT, ShadanS, and WeissU. Lipids in health and disease. Nature, 510: 47, 2014.
10.
HaoG, YuY, GuB, XingY, and XueM. Protective effects of berberine against doxorubicin-induced cardiotoxicity in rats by inhibiting metabolism of doxorubicin. Xenobiotica, 45: 1024–1029, 2015.
11.
HarrisonSC, HolmesMV, and HumphriesSE. Mendelian randomisation, lipids, and cardiovascular disease. Lancet, 380: 543–545, 2012.
12.
HegedusC, TelbiszA, HegedusT, SarkadiB, and Ozvegy-LaczkaC. Lipid regulation of the ABCB1 and ABCG2 multidrug transporters. Adv Cancer Res, 125: 97–137, 2015.
13.
IrwinME, MuellerKL, BohinN, GeY, and BoernerJL. Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J Cell Physiol, 226: 2316–2328, 2011.
14.
KaplanMJ. Cardiovascular complications of rheumatoid arthritis: assessment, prevention, and treatment. Rheum Dis Clin North Am, 36: 405–426, 2010.
15.
KathuriaM, BhattacharjeeA, SashidharaKV, SinghSP, and MitraK. Induction of mitochondrial dysfunction and oxidative stress in Leishmania donovani by orally active clerodane diterpene. Antimicrob Agents Chemother, 58: 5916–5928, 2014.
KheirMM, WangY, HuaL, HuJ, LiL, LeiF, and DuL. Acute toxicity of berberine and its correlation with the blood concentration in mice. Food Chem Toxicol, 48: 1105–1110, 2010.
18.
KimKH, LeeGY, KimJI, HamM, Won LeeJ, and KimJB. Inhibitory effect of LXR activation on cell proliferation and cell cycle progression through lipogenic activity. J Lipid Res, 51: 3425–3433, 2010.
19.
KongW, WeiJ, AbidiP, LinM, InabaS, LiC, WangY, WangZ, SiS, PanH, WangS, WuJ, LiZ, LiuJ, and JiangJD. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med, 10: 1344–1351, 2004.
20.
KosinskaMK, LiebischG, LochnitG, WilhelmJ, KleinH, KaesserU, LasczkowskiG, RickertM, SchmitzG, and SteinmeyerJ. A lipidomic study of phospholipid classes and species in human synovial fluid. Arthritis Rheum, 65: 2323–2333, 2013.
21.
LeeYS, KimWS, KimKH, YoonMJ, ChoHJ, ShenY, YeJM, LeeCH, OhWK, KimCT, Hohnen-BehrensC, GosbyA, KraegenEW, JamesDE, and KimJB. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes, 55: 2256–2264, 2006.
22.
LeungEL, CaoZW, JiangZH, ZhouH, and LiuL. Network-based drug discovery by integrating systems biology and computational technologies. Brief Bioinform, 14: 491–505, 2013.
23.
LeungEL, FanXX, WongMP, JiangZH, LiuZQ, YaoXJ, LuLL, ZhouYL, YauLF, TinVP, and LiuL. Targeting tyrosine kinase inhibitor-resistant non-small cell lung cancer by inducing epidermal growth factor receptor degradation via methionine 790 oxidation. Antioxid Redox Signal, 24: 263–279, 2016.
24.
LiX, FangP, MaiJ, ChoiET, WangH, and YangXF. Targeting mitochondrial reactive oxygen species as novel therapy for inflammatory diseases and cancers. J Hematol Oncol, 6: 19, 2013.
25.
LiY, XuS, MihaylovaMM, ZhengB, HouX, JiangB, ParkO, LuoZ, LefaiE, ShyyJY, GaoB, WierzbickiM, VerbeurenTJ, ShawRJ, CohenRA, and ZangM. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab, 13: 376–388, 2011.
26.
LiYC, ParkMJ, YeSK, KimCW, and KimYN. Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents. Am J Pathol 168: 1107–1118; quiz 140, 4–1405, 2006.
27.
MaceykaM and SpiegelS. Sphingolipid metabolites in inflammatory disease. Nature, 510: 58–67, 2014.
28.
Maradit-KremersH, NicolaPJ, CrowsonCS, BallmanKV, and GabrielSE. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum, 52: 722–732, 2005.
29.
MenendezJA and LupuR. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer, 7: 763–777, 2007.
30.
MoffattMF, GutIG, DemenaisF, StrachanDP, BouzigonE, HeathS, von MutiusE, FarrallM, LathropM, and CooksonWO. A large-scale, consortium-based genomewide association study of asthma. N Engl J Med, 363: 1211–1221, 2010.
31.
OhHY, LeeEJ, YoonS, ChungBH, ChoKS, and HongSJ. Cholesterol level of lipid raft microdomains regulates apoptotic cell death in prostate cancer cells through EGFR-mediated Akt and ERK signal transduction. Prostate, 67: 1061–1069, 2007.
32.
PandeyMK, SungB, KunnumakkaraAB, SethiG, ChaturvediMM, and AggarwalBB. Berberine modifies cysteine 179 of IkappaBalpha kinase, suppresses nuclear factor-kappaB-regulated antiapoptotic gene products, and potentiates apoptosis. Cancer Res, 68: 5370–5379, 2008.
33.
PincusT, YaziciY, SokkaT, AletahaD, and SmolenJS. Methotrexate as the “anchor drug” for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol, 21: S179–S185, 2003.
34.
QuQ, ZengF, LiuX, WangQJ, and DengF. Fatty acid oxidation and carnitine palmitoyltransferase I: emerging therapeutic targets in cancer. Cell Death Dis, 7: e2226, 2016.
35.
RuiL. Energy metabolism in the liver. Compr Physiol, 4: 177–197, 2014.
36.
SantosCR and SchulzeA. Lipid metabolism in cancer. FEBS J, 279: 2610–2623, 2012.
37.
SimonsK and IkonenE. Functional rafts in cell membranes. Nature, 387: 569–572, 1997.
38.
SimonsK and ToomreD. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol, 1: 31–39, 2000.
39.
SpiegelS and MilstienS. The outs and the ins of sphingosine-1-phosphate in immunity. Nat Rev Immunol, 11: 403–415, 2011.
40.
StorchCH, EhehaltR, HaefeliWE, and WeissJ. Localization of the human breast cancer resistance protein (BCRP/ABCG2) in lipid rafts/caveolae and modulation of its activity by cholesterol in vitro. J Pharmacol Exp Ther, 323: 257–264, 2007.
41.
SunH, WangH, ZhangA, YanG, ZhangY, AnN, and WangX. Berberine ameliorates nonbacterial prostatitis via multi-target metabolic network regulation. OMICS, 19: 186–195, 2015.
42.
TanW, LuJ, HuangM, LiY, ChenM, WuG, GongJ, ZhongZ, XuZ, DangY, GuoJ, ChenX, and WangY. Anti-cancer natural products isolated from chinese medicinal herbs. Chin Med, 6: 27, 2011.
43.
TascilarK, Dell'AnielloS, HudsonM, and SuissaS. Statins and risk of rheumatoid arthritis—a nested case–control study. Arthritis Rheumatol, 68: 2603–2611, 2016.
44.
TurnerN, LiJY, GosbyA, ToSW, ChengZ, MiyoshiH, TaketoMM, CooneyGJ, KraegenEW, JamesDE, HuLH, LiJ, and YeJM. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes, 57: 1414–1418, 2008.
45.
van der BliekAM, ShenQ, and KawajiriS. Mechanisms of mitochondrial fission and fusion. Cold Spring Harb Perspect Biol, 5: pii:a011072, 2013.
46.
WheatonWW, WeinbergSE, HamanakaRB, SoberanesS, SullivanLB, AnsoE, GlasauerA, DufourE, MutluGM, BudignerGS, and ChandelNS. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. eLife, 3: e02242, 2014.
47.
WijesekaraN, ZhangLH, KangMH, AbrahamT, BhattacharjeeA, WarnockGL, VerchereCB, and HaydenMR. miR-33a modulates ABCA1 expression, cholesterol accumulation, and insulin secretion in pancreatic islets. Diabetes, 61: 653–658, 2012.
48.
XiaX, YanJ, ShenY, TangK, YinJ, ZhangY, YangD, LiangH, YeJ, and WengJ. Berberine improves glucose metabolism in diabetic rats by inhibition of hepatic gluconeogenesis. PLoS One, 6: e16556, 2011.
49.
YangW, BaiY, XiongY, ZhangJ, ChenS, ZhengX, MengX, LiL, WangJ, XuC, YanC, WangL, ChangCC, ChangTY, ZhangT, ZhouP, SongBL, LiuW, SunSC, LiuX, and LiBL. Potentiating the antitumour response of CD8(+) T cells by modulating cholesterol metabolism. Nature, 531: 651–655, 2016.
50.
YinJ, XingH, and YeJ. Efficacy of berberine in patients with type 2 diabetes mellitus. Metab Clin Exp, 57: 712–717, 2008.
51.
ZhangX, GuL, LiJ, ShahN, HeJ, YangL, HuQ, and ZhouM. Degradation of MDM2 by the interaction between berberine and DAXX leads to potent apoptosis in MDM2-overexpressing cancer cells. Cancer Res, 70: 9895–9904, 2010.
52.
ZhaoH, ZhangT, XiaC, ShiL, WangS, ZhengX, HuT, and ZhangB. Berberine ameliorates cartilage degeneration in interleukin-1beta-stimulated rat chondrocytes and in a rat model of osteoarthritis via Akt signalling. J Cell Mol Med, 18: 283–292, 2014.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
